Showing 1401-1410 of 4003 results for "".
Understanding the Legalities of Off-label Use
https://practicaldermatology.com/topics/practice-management/understanding-the-legalities-of-off-label-use/20317/Off-label use is part and parcel of dermatology practice, but confusion about the practice persists. Here's what you should know.Repairing the Ellipse; Resident Salary Update
https://practicaldermatology.com/youngmd-connect/resident-resource-center/repairing-the-ellipse-resident-salary-update/20414/Subcision Plus Sublative Technologies to Treat Acne Scars
https://practicaldermatology.com/topics/general-topics/subcision-plus-sublative-technologies-to-treat-acne-scars/20462/Combining something old and something new to create something skintastic.Five Things Every Dermatologist Should Know About Visual Content
https://practicaldermatology.com/topics/practice-management/five-things-every-dermatologist-should-know-about-visual-content/20597/Point/Counterpoint: Is There a Role for Permanent Fillers?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/pointcounterpoint-is-there-a-role-for-permanent-fillers/20916/“Skin May Be Deep, But Dermatologists Are Superficial…”
https://practicaldermatology.com/topics/general-topics/skin-may-be-deep-but-dermatologists-are-superficial/21254/Fillers: Tips and Tools for Beginning and Honing Your Practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/fillers-tips-and-tools-for-beginning-and-honing-your-practice/21625/Starting out small and adding new techniques one at a time is critical in the use of fillers in practice.Recent Developments: What's Next for the Dermatology Pharmaceutical Industry?
https://practicaldermatology.com/columns/recent-developments/whats-next-for-the-dermatology-pharmaceutical-industry/21974/No doubt the dermatology pharmaceutical industry is undergoing a change. But what does it mean?Mycosis Fungoides: Diagnosis and Work-up of Early Stage Disease
https://practicaldermatology.com/topics/general-topics/mycosis-fungoides-diagnosis-and-work-up-of-early-stage-disease/22004/The ability to differentiate MF from mimickers permits early diagnosis and treatment, potentially improving long-term outcomes.Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
https://practicaldermatology.com/programs/cme/efficacy-and-safety-outcomes-for-adjuvant-immunotherapy-driving-guideline-recommendations-for-stage-iiiiv-melanoma/36325/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.